glp-1 therapy protein intake optimization research GLP-1 Agonist: The Good, the Bad and the Ugly Beyond GLP-1 Agonists: An Adaptive

This article examines the evidence for blood pressure reduction with GLP-1 therapy, identifies which patients may benefit most from this additional effect, and outlines important safety considerations

Gastrointestinal issues Severe gastrointestinal conditions: Individuals may experience worsening of existing stomach and digestion issues when taking GLP-1 medications

Berberine is not part of these evidence-based pathways

But the gap between "berberine has some evidence when swallowed at 1,500 mg" and "a patch with 8.75 mg of berberine will help you lose weight through your skin" is a canyon, and the marketing fills that canyon with aspiration rather than data

doi: 10.1002/mnfr.200700048 113 BowkerNHansfordRBurgessSFoleyCNAuyeungVPWErzurumluogluAMet al